Literature DB >> 20939995

CD8+ gamma-delta TCR+ and CD4+ T cells produce IFN-γ at 5-7 days after yellow fever vaccination in Indian rhesus macaques, before the induction of classical antigen-specific T cell responses.

Patrícia C C Neves1, Richard A Rudersdorf, Ricardo Galler, Myrna C Bonaldo, Marlon Gilsepp Veloso de Santana, Philip A Mudd, Maurício A Martins, Eva G Rakasz, Nancy A Wilson, David I Watkins.   

Abstract

The yellow fever 17D (YF-17D) vaccine is one of the most efficacious vaccines developed to date. Interestingly, vaccination with YF-17D induces IFN-γ production early after vaccination (days 5-7) before the development of classical antigen-specific CD8(+) and CD4(+) T cell responses. Here we investigated the cellular source of this early IFN-γ production. At days 5 and 7 post-vaccination activated CD8(+) gamma-delta TCR T cells produced IFN-γ and TNF-α. Activated CD4(+) T cells produced IFN-γ and TNF-α at day 7 post-vaccination. This early IFN-γ production was also induced after vaccination with recombinant YF-17D (rYF-17D), but was not observed after recombinant Adenovirus type 5 (rAd5) vaccination. Early IFN-γ production, therefore, might be an important aspect of yellow fever vaccination.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20939995      PMCID: PMC3179417          DOI: 10.1016/j.vaccine.2010.09.090

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  22 in total

1.  gammadelta T cells promote the maturation of dendritic cells during West Nile virus infection.

Authors:  Hao Fang; Thomas Welte; Xin Zheng; Gwong-Jen J Chang; Michael R Holbrook; Lynn Soong; Tian Wang
Journal:  FEMS Immunol Med Microbiol       Date:  2010-02-17

2.  Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization?

Authors:  M A Martins; M L Silva; A P V Marciano; V Peruhype-Magalhães; S M Eloi-Santos; j G L Ribeiro; R Correa-Oliveira; A Homma; E G Kroon; A Teixeira-Carvalho; O A Martins-Filho
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

3.  Assessment of yellow fever epidemic risk--a decision-making tool for preventive immunization campaigns.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2007-05-04

4.  Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection.

Authors:  Bimmi Shrestha; Tian Wang; Melanie A Samuel; Kevin Whitby; Joe Craft; Erol Fikrig; Michael S Diamond
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

5.  Recombinant yellow fever vaccine virus 17D expressing simian immunodeficiency virus SIVmac239 gag induces SIV-specific CD8+ T-cell responses in rhesus macaques.

Authors:  Myrna C Bonaldo; Mauricio A Martins; Richard Rudersdorf; Philip A Mudd; Jonah B Sacha; Shari M Piaskowski; Patrícia C Costa Neves; Marlon G Veloso de Santana; Lara Vojnov; Saverio Capuano; Eva G Rakasz; Nancy A Wilson; John Fulkerson; Jerald C Sadoff; David I Watkins; Ricardo Galler
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

6.  Neutralizing F(ab')2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis.

Authors:  J J Schlesinger; S Chapman
Journal:  J Gen Virol       Date:  1995-01       Impact factor: 3.891

7.  The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice.

Authors:  J J Schlesinger; M Foltzer; S Chapman
Journal:  Virology       Date:  1993-01       Impact factor: 3.616

8.  Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes.

Authors:  Giovanna Barba-Spaeth; Randy S Longman; Matthew L Albert; Charles M Rice
Journal:  J Exp Med       Date:  2005-10-31       Impact factor: 14.307

Review 9.  Antiviral reactivities of gammadelta T cells.

Authors:  Fabrizio Poccia; Chiara Agrati; Federico Martini; Maria Rosaria Capobianchi; Marianne Wallace; Miroslav Malkovsky
Journal:  Microbes Infect       Date:  2005-03-03       Impact factor: 2.700

10.  Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity.

Authors:  Troy Querec; Soumaya Bennouna; Sefik Alkan; Yasmina Laouar; Keith Gorden; Richard Flavell; Shizuo Akira; Rafi Ahmed; Bali Pulendran
Journal:  J Exp Med       Date:  2006-02-06       Impact factor: 14.307

View more
  16 in total

Review 1.  The yellow fever 17D virus as a platform for new live attenuated vaccines.

Authors:  Myrna C Bonaldo; Patrícia C Sequeira; Ricardo Galler
Journal:  Hum Vaccin Immunother       Date:  2014-02-19       Impact factor: 3.452

2.  Improved genetic stability of recombinant yellow fever 17D virus expressing a lentiviral Gag gene fragment.

Authors:  Marlon G Veloso de Santana; Patrícia C C Neves; Juliana Ribeiro dos Santos; Noemia S Lima; Alexandre A C dos Santos; David I Watkins; Ricardo Galler; Myrna C Bonaldo
Journal:  Virology       Date:  2014-02-08       Impact factor: 3.616

Review 3.  Are Th17 Cells Playing a Role in Immunity to Dermatophytosis?

Authors:  Marie-Pierre Heinen; Ludivine Cambier; Laurence Fievez; Bernard Mignon
Journal:  Mycopathologia       Date:  2016-11-23       Impact factor: 2.574

4.  Plant-Produced Subunit Vaccine Candidates against Yellow Fever Induce Virus Neutralizing Antibodies and Confer Protection against Viral Challenge in Animal Models.

Authors:  Stephen Tottey; Yoko Shoji; R Mark Jones; Jessica A Chichester; Brian J Green; Konstantin Musiychuk; Huaxin Si; Slobodanka D Manceva; Amy Rhee; Moneim Shamloul; Joey Norikane; Rosane C Guimarães; Elena Caride; Andrea N M R Silva; Marisol Simões; Patricia C C Neves; Renato Marchevsky; Marcos S Freire; Stephen J Streatfield; Vidadi Yusibov
Journal:  Am J Trop Med Hyg       Date:  2017-11-30       Impact factor: 2.345

5.  Early HIV infection is associated with reduced proportions of gamma delta T subsets as well as high creatinine and urea levels.

Authors:  Babatunde A Olusola; Dieter Kabelitz; David O Olaleye; Georgina N Odaibo
Journal:  Scand J Immunol       Date:  2020-02-19       Impact factor: 3.487

Review 6.  Six-of-the-best: unique contributions of γδ T cells to immunology.

Authors:  Pierre Vantourout; Adrian Hayday
Journal:  Nat Rev Immunol       Date:  2013-02       Impact factor: 53.106

Review 7.  Current status and future prospects of yellow fever vaccines.

Authors:  Andrew S Beck; Alan D T Barrett
Journal:  Expert Rev Vaccines       Date:  2015-09-14       Impact factor: 5.217

8.  HPV16 E5 peptide vaccine in treatment of cervical cancer in vitro and in vivo.

Authors:  Shu-Jie Liao; Dong-Rui Deng; Dan Zeng; Ling Zhang; Xiao-Ji Hu; Wei-Na Zhang; Li Li; Xue-Feng Jiang; Chang-Yu Wang; Jian-Feng Zhou; Shi-Xuan Wang; Han-Wang Zhang; Ding Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-10-20

9.  Immunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaques.

Authors:  Mauricio A Martins; Myrna C Bonaldo; Richard A Rudersdorf; Shari M Piaskowski; Eva G Rakasz; Kim L Weisgrau; Jessica R Furlott; Christopher M Eernisse; Marlon G Veloso de Santana; Bertha Hidalgo; Thomas C Friedrich; Maria J Chiuchiolo; Christopher L Parks; Nancy A Wilson; David B Allison; Ricardo Galler; David I Watkins
Journal:  PLoS One       Date:  2013-01-15       Impact factor: 3.240

10.  Recombinant yellow fever viruses elicit CD8+ T cell responses and protective immunity against Trypanosoma cruzi.

Authors:  Raquel Tayar Nogueira; Alanderson Rocha Nogueira; Mirian Claudia Souza Pereira; Maurício Martins Rodrigues; Patrícia Cristina da Costa Neves; Ricardo Galler; Myrna Cristina Bonaldo
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.